Breaks Categories: News

MondayJun 19, 2017 12:25 pm

NetworkNewsBreaks – Rigel Pharmaceuticals, Inc.’s (NASDAQ: RIGL) Shares Rise on FDA Accepting TAVALISSE™ NDA to Treat Chronic ITP

Shares of Rigel Pharmaceuticals (NASDAQ: RIGL) climbed 17% higher this morning after the company said the U.S. Food and Drug Administration (FDA) has filed its New Drug Application (NDA) for the use of TAVALISSE™ in patients with chronic or persistent immune thrombocytopenia (ITP). Data from all studies, such as preclinical evaluation and drug manufacturing data, were included in the NDA submission. Based on the Prescription Drug User Fee Act, Rigel anticipates the action date for the FDA to complete its review will be April 17, 2018. The FDA has previously granted Orphan Drug designation to TAVALISSE™ for the treatment of…

Continue Reading

MondayJun 19, 2017 12:22 pm

NetworkNewsBreaks – ReWalk Robotics (NASDAQ: RWLK) Shares Soar on Prototype Demonstration of Restore Soft Suit Exoskeleton for Stroke Patients

ReWalk Robotics (NASDAQ: RWLK) shares soared 32% higher following the company’s unveiling of a Restore prototype on Yahoo Finance. Collaborators from Harvard University's Wyss Institute for Biologically Inspired Engineering joined ReWalk’s CEO Larry Jasinski to showcase the prototype of the soft suit exoskeleton intended to assist stroke survivors and demonstrate how the system works. Delivery of a commercial Restore soft suit is anticipated for 2018. "With the prototype finished, we are eager to begin clinical studies and pursue regulatory approvals so that these systems can be provided to millions of patients who can benefit from access to the device," CEO…

Continue Reading

FridayJun 16, 2017 12:32 pm

NetworkNewsBreaks – Medovex Corp. (NASDAQ: MDVX) Receives Initial Commercial Orders for DenerveX™ System Following CE Mark Approval in Europe

Medovex (NASDAQ: MDVX) this morning said it has received its first three commercial orders for its DenerveX™ System following the system’s CE mark approval earlier this month. The orders include both the DenerveX Kit containing the DenerveX Device and the DenerveX Pro-40 Generators for Germany, the UK and Italy. "Receiving multiple orders from three of our distributors so closely on the heels of our recent receipt of CE Mark clearly gives us reason for cautious optimism. We are pleased to be building atop of our recent accomplishment of receiving CE Mark, not just for our shareholders, but for all of…

Continue Reading

FridayJun 16, 2017 12:04 pm

NetworkNewsBreaks – Sky Solar Holdings (NASDAQ: SKYS) Shares Plummet on Independent Director Change; Forms Independent Committee to Investigate Former CEO’s Conduct

Shares of Sky Solar Holdings (NASDAQ: SKYS) are down 24% this morning after the company said Glen Wei resigned as an independent director of the company effective June 14, 2017. Following Wei’s resignation, Sky Solar appointed Xuelong Pei as an independent director, effective June 15, 2017. Pei will also serve on the audit committee, compensation committee and nominating and corporate governance committee of the board. Additionally, Sky Solar established an independent committee to investigate the conduct of former chief executive officer Weili Su involving transactions and fund transfers that seem to be missing proper board and audit committee authorization. The…

Continue Reading

FridayJun 16, 2017 12:01 pm

NetworkNewsBreaks – Lonestar Resources (NASDAQ: LONE) Closes Eagle Ford Shale Acquisitions

Lonestar Resources (NASDAQ: LONE) this morning said it has closed on the previously announced Eagle Ford Shale acquisitions in Karnes, Gonzales, DeWitt, Lavaca and Fayette Counties. The acquisition comprises of approximately 30,219 gross or 21,238 net acres. Lonestar has previously estimated the area to have proven reserves of approximately 31.4 million barrels of oil equivalent. The company paid approximately $110.6 million to close the transaction, consisting of $99 million in cash and approximately 2.7 million shares of its Class B Convertible Preferred Stock. Lonestar's senior secured facility was increased from $112 million to $160 million after closing these acquisitions. Additionally,…

Continue Reading

FridayJun 16, 2017 9:21 am

NetworkNewsBreaks – Kootenay Zinc Corp. (CSE: ZNK) (OTCQB: KTNNF) Offers Update on Sully Project Exploration

Mineral exploration and development company Kootenay Zinc Corp. (CSE: ZNK) (OTCQB: KTNNF) this morning issued an update on its exploration activities and upcoming drill testing at the Sully project. Notably, field programs have continued through May and early June with a specific focus on the company’s E3 target, including detailed gravity surveying, interpretation and mass modeling, prospecting and mapping, soil geochemistry sampling, drilling preparations and road/access preparations. Excel Geophysics recently completed interpretation and mass modeling of this new data, identifying a “well-defined, sizeable and discreet anomaly at this target location.” Brian Jones, principle of Excel Geophysics, noted E3’s attractiveness as…

Continue Reading

ThursdayJun 15, 2017 3:52 pm

NetworkNewsBreaks – MYM Nutraceuticals, Inc. (MYMMF) Appoints New Executive Chairman; Details Insider Share Purchases

MYM Nutraceuticals (CSE: MYM) (OTC: MYMMF) earlier this month appointed Erick Factor to the company’s board of directors and as executive chairman. As the founder of Vancouver-based “Westcoast Medicann” dispensary, Factor has 20 years of experience in cultivating medical marijuana and manufacturing cannabis by-products, and he has provided medical marijuana to thousands of patients over the past two decades. Additionally, the company released a list of company insiders who bought shares in the last private placement at $0.18; total proceeds from insider share purchases totaled $343,137.96. To view the full press release, visit: http://nnw.fm/e8PuU About MYM MYM Nutraceuticals Inc. (CSE:MYM)…

Continue Reading

ThursdayJun 15, 2017 12:12 pm

NetworkNewsBreaks – ShotSpotter, Inc. (NASDAQ: SSTI) Closes IPO, Raising $34.5M

ShotSpotter (NASDAQ: SSTI) recently announced the closing of its initial public offering of common stock. The gunfire detection and solutions company sold to the underwriters 3,220,000 shares of common stock at a public offering price of $11 per share, which includes the underwriters’ fully exercised over-allotment option of 420,000 shares. Before deducting underwriting discounts and commissions and estimated offering expenses, total proceeds from the offering totaled approximately $35.4 million. Roth Capital Partners acted as the sole book-running manager for the offering and as the representative of the underwriters. Northland Capital Markets acted as co-lead manager and Imperial Capital acted as…

Continue Reading

ThursdayJun 15, 2017 8:51 am

NetworkNewsBreaks – Player’s Network, Inc. (PNTV) Bolsters Leadership Team through Addition of Nevada Assistant Controller Geoffrey Lawrence as CFO, CCO

Player’s Network, Inc. (OTCQB: PNTV) this morning announced its appointment of Nevada Assistant Controller Geoffrey Lawrence as the company’s chief financial officer and chief compliance officer, effective July 1, 2017. “Geoffrey is a senior-level operator who will help us fulfill our commitment to our shareholders and the investment community insofar as our goals of increased transparency and stronger corporate governance,” Mark Bradley, CEO of PNTV, stated in the news release. “As PNTV continues to grow its assets, it is necessary that we assemble a strong first-class management team, and Geoffrey is a perfect fit, bringing to the table the necessary…

Continue Reading

WednesdayJun 14, 2017 2:11 pm

NetworkNewsBreaks – Sorrento Therapeutics, Inc.’s (NASDAQ: SRNE) Pain Subsidiary Reports Positive Data from Adhesion Study of ZTlido™; Shares Higher

Shares of Sorrento Therapeutics (NASDAQ: SRNE) are up 7% mid-day after the company’s pain subsidiary, SCILEX Pharmaceuticals, released positive data regarding its lead investigational product, ZTlido™. During a recently completed comparative adhesion performance study to support the market authorization application (MAA) in the EU, ZTlido™ demonstrated superior adhesion versus the EU reference product, Versatis®. SCILEX said it plans to resubmit the New Drug Application for ZTlido™ to the FDA and the MAA to the Medicines and Healthcare Products Regulatory Agency in the United Kingdom in the second half of 2017. "We are pleased to report our noteworthy data. We believe…

Continue Reading